MBL International Corporation Introduces AngioPhase(TM) Angiogenesis Kit
Product News Feb 10, 2012
Angiogenesis is the multistep process whereby new blood vessels develop from pre-existing vasculature. It plays a key role in the natural process of healing and reproduction but also in many pathological processes including cancer, skin diseases, age-related blindness, diabetic ulcers, cardiovascular disease, and stroke.
AngioPhase(TM) incorporates a patented technology, developed by TCS Cellworks Limited, Buckingham, UK, in which human endothelial cells are co-cultured with other human cells in a specially designed medium. Under the terms of the non-exclusive agreement with TCS Cellworks Limited, MBL International Corporation has been granted a license to manufacture and sell the assay in North and South America.
"MBL International is excited about adding AngioPhase to our growing portfolio of life sciences products," said Dennis Walczewski, CEO MBL International Corporation. "This technology offers many benefits to researchers in the biotechnology and pharmaceutical industries by offering a ready-to-use angiogenesis kit in which test compounds can be added at any time. Moreover, both angiogenic simulators and inhibitors can be assessed as well as tubule formation."
"We are pleased to enter into this licensing agreement with MBL International Corporation," stated Tim Almond CEO of TCS Cellworks. "They have demonstrated not only a strong commitment to manufacturing high quality products but also an impressive business model which leverages the superior technical expertise of their commercial team."